EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

In today's fast-paced world, respiratory health is often neglected, especially for those suffering from chronic conditions ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Australia's Therapeutic Goods Administration (TGA) recently issued a safety alert requiring extra warnings to be included ...

MILLIONS of Brits with asthma are potentially risking their lives by not using their inhaler properly, UK experts have warned The UK has one worst death rates from the lung condition in ...